The objective of this study is to follow, characterize and evaluate the natural history of the disease course, burden of illness, risk factors, quality of life (QoL), and biomarkers associated with disease progression and treatments in pediatric patients with cardiomyopathy (CM) due to MYBPC3 pathogenic or likely pathogenic mutations.
This is a natural history study.
Children with a type of cardiomyopathy caused by a specific genetic mutation (MYBPC3 mutation) may be included in this research study.
Principal Investigator